The Repo homeodomain transcription factor suppresses hematopoiesis in Drosophila and preserves the glial fate

  1. Angela Giangrande1,2,3,4
  1. 1Institut de Génétique et de Biologie Moléculaire et Cellulaire, 67400 Illkirch, France
  2. 2Centre National de la Recherche Scientifique, UMR7104, 67400 Illkirch, France
  3. 3Institut National de la Santé et de la Recherche Médicale, U964, 67400 Illkirch, France
  4. 4Université de Strasbourg, 67404 Illkirch, France
  5. 5Department of Basic and Clinical Neuroscience, King's College London, 125 Coldharbour Lane, SE5 9NU, London, United Kingdom
  6. 6Institute of Science and Technology Austria, Am Campus 1, 3400 Klosterneuburg, Austria
  1. Corresponding author: Angela Giangrande, Phone: (33)388653381, Fax: (33)388653201, E-mail: angela{at}igbmc.fr
  1. Author contributions: G.T. designed research; G.T., P.B.C., and D.M. performed research; G.T., P.B.C., J.Z., D.M., M.F., and A.G. analyzed data; G.T. wrote the first draft of the paper; G.T., P.B.C., and A.G. edited the paper; D.S. contributed unpublished reagents/analytic tools; A.G. wrote the paper.

Abstract

Despite their different origins, Drosophila glia and hemocytes are related cell populations that provide an immune function. Drosophila hemocytes patrol the body cavity and act as macrophages outside the nervous system whereas glia originate from the neuroepithelium and provide the scavenger population of the nervous system. Drosophila glia are hence the functional orthologs of vertebrate microglia, even though the latter are cells of immune origin that subsequently move into the brain during development. Interestingly, the Drosophila immune cells within (glia) and outside the nervous system (hemocytes) require the same transcription factor Glide/Gcm for their development. This raises the issue of how do glia specifically differentiate in the nervous system and hemocytes in the procephalic mesoderm. The Repo homeodomain transcription factor and pan-glial direct target of Glide/Gcm is known to ensure glial terminal differentiation. Here we show that Repo also takes center stage in the process that discriminates between glia and hemocytes. First, Repo expression is repressed in the hemocyte anlagen by mesoderm-specific factors. Second, Repo ectopic activation in the procephalic mesoderm is sufficient to repress the expression of hemocyte-specific genes. Third, the lack of Repo triggers the expression of hemocyte markers in glia. Thus, a complex network of tissue-specific cues biases the potential of Glide/Gcm. These data allow us to revise the concept of fate determinants and help us understand the bases of cell specification. Both sexes were analyzed.

SIGNIFICANCE STATEMENT

Distinct cell types often require the same pioneer transcription factor, raising the issue of how does one factor trigger different fates. In Drosophila, glia and hemocytes provide a scavenger activity within and outside the nervous system, respectively. While they both require the Glide/Gcm transcription factor, glia originate from the ectoderm, hemocytes from the mesoderm. Here we show that tissue-specific factors inhibit the gliogenic potential of Glide/Gcm in the mesoderm by repressing the expression of the homeodomain protein Repo, a major glial-specific target of Glide/Gcm. Repo expression in turn inhibits the expression of hemocyte-specific genes in the nervous system. These cell-specific networks secure the establishment of the glial fate only in the nervous system and allow cell diversification.

Footnotes

  • The authors declare no competing financial interests.

  • We thank B. Altenhein, K. Brückner, M. Crozatier, L. Waltzer, M. Logan, E. Kurant, R. Reuter, E. Kurucz, J.L Dimarcq, J. Hoffmann, C. Goodman, the DHSB and the Bloomington Stock Center for reagents and flies. We thank all the lab members for comments on the manuscript, C. Diebold, C. Delaporte, M. Pezze, the fly, imaging and antibody facilities for technical assistance and D. Dembele for help with statistics. We thank Alison Brewer for help with Luciferase assays. This work was supported by INSERM, CNRS, UDS, Ligue Régionale contre le Cancer, Hôpital de Strasbourg, ARC and ANR grants. P. Cattenoz was funded by the ANR and by the ARSEP, G Trebuchet by governmental and by ARC fellowships. This work was also supported by grants from the Ataxia UK (2491) and the NC3R (NC/L000199/1) awarded to M.F. The IGBMC was also supported by a French state fund through the ANR labex. D.E.S. was funded by Marie Curie CIG 334077/IRTIM.

  • Received April 25, 2018.
  • Revision received October 8, 2018.
  • Accepted October 12, 2018.